HighVista Strategies LLC Invests $820,000 in CytomX Therapeutics, Inc. $CTMX

HighVista Strategies LLC purchased a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 257,148 shares of the biotechnology company’s stock, valued at approximately $820,000. HighVista Strategies LLC owned approximately 0.15% of CytomX Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CTMX. Farther Finance Advisors LLC acquired a new position in CytomX Therapeutics during the third quarter worth $25,000. Invesco Ltd. purchased a new stake in CytomX Therapeutics in the 2nd quarter valued at $32,000. Pursue Wealth Partners LLC acquired a new stake in shares of CytomX Therapeutics in the 2nd quarter worth $33,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of CytomX Therapeutics in the 3rd quarter worth $34,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of CytomX Therapeutics during the 1st quarter worth $39,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Piper Sandler boosted their price target on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Oppenheimer restated an “outperform” rating and set a $12.00 price objective on shares of CytomX Therapeutics in a research report on Monday. Barclays lifted their target price on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Guggenheim reissued a “buy” rating and issued a $10.00 price target on shares of CytomX Therapeutics in a research note on Monday, March 9th. Finally, Cantor Fitzgerald raised their price target on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Eight analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.88.

CytomX Therapeutics Stock Up 44.2%

CTMX opened at $6.75 on Tuesday. CytomX Therapeutics, Inc. has a 52 week low of $0.40 and a 52 week high of $8.21. The business has a fifty day simple moving average of $5.24 and a 200-day simple moving average of $4.07. The firm has a market cap of $1.14 billion, a P/E ratio of 16.88 and a beta of 2.44.

CytomX Therapeutics News Summary

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Phase 1 expansion data show solid activity in late‑line colorectal cancer — confirmed response rates of 32% at 10 mg/kg Q3W and 20% at 8.6 mg/kg Q3W, estimated PFS ~7.1 months at the higher dose, and manageable safety with ongoing dose optimization. Management is targeting mid‑year FDA interactions to align on a potential registrational trial. Varsetatug Masetecan Continues to Demonstrate Positive Data
• Positive Sentiment: Analyst upgrades and higher price targets lifted sentiment — HC Wainwright raised its target to $17 (buy) and JPMorgan upgraded CTMX to overweight with a $12 target; Seeking Alpha and Benzinga published bullish takes tying valuation to Varseta‑M’s late‑line mCRC opportunity. These notes reinforced upside expectations. Mid‑Cap CytomX Therapeutics’ Colorectal Cancer Data Fuels Stock Rally
• Neutral Sentiment: Market reaction and high trading volume: CTMX experienced unusually heavy volume and a large pre‑market move as headlines circulated and investors digested the clinical readout plus analyst commentary. That amplifies intraday volatility but is informational rather than fundamental by itself. Why CTMX Stock Is Soaring Pre‑Market
• Negative Sentiment: Proposed $250M underwritten public offering of common stock and pre‑funded warrants — the financing will be dilutive and typically weighs on near‑term per‑share metrics despite extending the cash runway for development. CytomX Announces Proposed Public Offering
• Negative Sentiment: Q4 miss on EPS and revenue — CTMX reported a ($0.22) EPS vs. consensus (~$0.08 loss) and revenue well below estimates, reinforcing near‑term cash burn and highlighting the company remains pre‑commercial. These fundamentals contrast with the positive clinical news. CTMX Reports Q4 Loss, Misses Revenue Estimates

CytomX Therapeutics Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.